JUST IN • MarketWatch.com - Top Stories
This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock soared.
READ ORIGINAL REPORT ↗THIS JUST HAPPENED PACKAGES THE WORLD INTO A FAST LIVE FEED SOURCE REPORTING STAYS ONE CLICK AWAY
